AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24247188 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 74
Study 21661618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (bedside counselling, take-home materials, 7 post-discharge telephone counselling calls over 2 months)
Number of subjects: 616
Study 21661618 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (advice and pamphlets)
Number of subjects: 616
Study 21661618 — intervention group
Group type: EXPERIMENTAL
Intervention: No pharmacotherapy
Number of subjects: 616
Study 21661618 — intervention group
Group type: EXPERIMENTAL
Intervention: With pharmacotherapy
Number of subjects: 616
Study 21661618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CVD
Number of subjects: 616
Study 21661618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with other diagnoses
Number of subjects: 616
Study 19704167 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated (treatment-naive) group
Number of subjects: 159
Study 19704167 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC-resistant group
Number of subjects: 159
Study 16722839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Number of subjects: 12
Study 14572305 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of oral magnesium citrate every 8 h for 5 days (prevention trial)
Number of subjects: 61
Study 14572305 — intervention group
Group type: COMPARATOR
Intervention: 4 g of intravenous magnesium sulphate (treatment trial)
Number of subjects: 61
Study 11262213 — intervention group
Group type: EXPERIMENTAL
Intervention: hPIV3 maternal antibody
Number of subjects: 0
Study 9151912 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with epirubicin (40 mg/m2 intra-arterial at 1 month after resection, followed by intravenous administration of 40 mg/m2 every 3 months for 2 years) and carmofur (300 mg/d orally for 24 months)
Number of subjects: 57
Study 9151912 — intervention group
Group type: COMPARATOR
Intervention: Control group undergoing resection only
Number of subjects: 57
Study 8486887 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-strenuous physical exercise (15 minutes)
Number of subjects: 20
Study 8486887 — intervention group
Group type: COMPARATOR
Intervention: Control group (watched a video of similar exercises for 15 minutes)
Number of subjects: 20
Study 3122628 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS NG 10 mg/24 h
Number of subjects: 20
Study 29439289 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5 (adalimumab biosimilar)
Number of subjects: 542
Study 29439289 — intervention group
Group type: COMPARATOR
Intervention: ADA (reference adalimumab)
Number of subjects: 542
Study 29439289 — intervention group
Group type: COMPARATOR
Intervention: ADA/SB5 group (switched from ADA to SB5)
Number of subjects: 542
Study 29439289 — intervention group
Group type: COMPARATOR
Intervention: ADA/ADA group (continued ADA)
Number of subjects: 542
Study 29439289 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5 group (continued SB5)
Number of subjects: 542
Study 29439289 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 542
Study 28789663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate treatment
Number of subjects: 0
Study 28789663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26536702 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden voice capsule
Number of subjects: 60
Study 26536702 — intervention group
Group type: COMPARATOR
Intervention: Golden voice capsule and omeprazole
Number of subjects: 60
Study 24011069 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2405319 (3, 10, or 20 mg daily for 28 days)
Number of subjects: 0
Study 24011069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21170803 — intervention group
Group type: EXPERIMENTAL
Intervention: One-arm maximal strength training
Number of subjects: 23
Study 21170803 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 19999220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural nerve conduction studies measuring sensory nerve conduction velocity (SNCV) and sensory latency (SNSL)
Number of subjects: 25
Study 19999220 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related impact on SNCV and SNSL
Number of subjects: 25
Study 12854339 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and behavioral interventions
Number of subjects: 2720
Study 12854339 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and behavioral interventions (high quality studies)
Number of subjects: 2720
Study 12854339 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and behavioral interventions (low quality studies)
Number of subjects: 2720
Study 10758471 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 207
Study 10758471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg)
Number of subjects: 207
Study 10758471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 207
Study 8885949 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm inhaled nitric oxide
Number of subjects: 0
Study 8885949 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without inhaled nitric oxide
Number of subjects: 0
Study 1570886 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml 0.5% bupivacaine/median approach
Number of subjects: 250
Study 1570886 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml 0.5% bupivacaine/paramedian approach
Number of subjects: 250
Study 1570886 — intervention group
Group type: COMPARATOR
Intervention: paramedian approach (group II)
Number of subjects: 250
Study 4091235 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 14
Study 4091235 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide
Number of subjects: 14
Study 4091235 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 14
Study 4091235 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 14
Study 30895203 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 30895203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26844723 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-dose therapy (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily)
Number of subjects: 200
Study 26844723 — intervention group
Group type: COMPARATOR
Intervention: Low-dose therapy (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily)
Number of subjects: 200
Study 26844723 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-dose therapy
Number of subjects: 200
Study 26844723 — intervention group
Group type: COMPARATOR
Intervention: Low-dose therapy
Number of subjects: 200
Study 26844723 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy
Number of subjects: 200
Study 26844723 — intervention group
Group type: COMPARATOR
Intervention: Low-dose and normal-dose groups
Number of subjects: 200
Study 26440297 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine filling pressure of 30 mm Hg
Number of subjects: 240
Study 26440297 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine filling pressure of 50 mm Hg
Number of subjects: 240
Study 26440297 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine filling pressure of 80 mm Hg
Number of subjects: 240
Study 26440297 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 240
Study 24649831 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weekly educational sessions promoting healthful nutrition and physical activity
Number of subjects: 306
Study 24649831 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 22735037 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-sea air dive to 30 msw for 30 min
Number of subjects: 15
Study 22735037 — intervention group
Group type: COMPARATOR
Intervention: Head-out water immersion for 30 min
Number of subjects: 15
Study 20613476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosyntropin (1 mg intravenously)
Number of subjects: 90
Study 20613476 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90
Study 17625622 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III with Dyract AP (Dentsply)
Number of subjects: 15
Study 17625622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop with Z2000 (3M Espe)
Number of subjects: 15
Study 17625622 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 15702438 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular pulsatile insulin release pattern
Number of subjects: 10
Study 15702438 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular pulse frequency insulin release pattern
Number of subjects: 10
Study 15702438 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular pulse amplitude insulin release pattern
Number of subjects: 10
Study 15702438 — intervention group
Group type: EXPERIMENTAL
Intervention: Very fast-pulsatile insulin release pattern
Number of subjects: 10
Study 15702438 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant insulin infusion
Number of subjects: 10
Study 12083474 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered lorazepam before surgery
Number of subjects: 144
Study 12083474 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to relaxing music through headphones before surgery
Number of subjects: 144
Study 12083474 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking to the operating room
Number of subjects: 144
Study 12083474 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to relaxing music through headphones during surgery
Number of subjects: 144
Study 12083474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sedation
Number of subjects: 144
Study 12083474 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional local anesthesia
Number of subjects: 144
Study 12083474 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 144
Study 10431116 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of zinc (group Z)
Number of subjects: 412
Study 10431116 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of zinc with additional vitamins and minerals (group Z+VM)
Number of subjects: 412
Study 10431116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 412
Study 8588794 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% carbohydrate‐electrolyte drink
Number of subjects: 0
Study 8588794 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% carbohydrate‐electrolyte drink containing 1% glycerol
Number of subjects: 0
Study 8588794 — intervention group
Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 0
Study 2699176 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anaesthetic with supplementary general anaesthetic (group I)
Number of subjects: 14
Study 2699176 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic as usual (group II)
Number of subjects: 14
Study 778989 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (4.55 g daily)
Number of subjects: 48
Study 778989 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-encapsulated aspirin (4.50 g daily)
Number of subjects: 48
Study 778989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 778989 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 48
Study 778989 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-encapsulated aspirin
Number of subjects: 48
Study 778989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aspirin preparations
Number of subjects: 48
Study 30706087 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous impaction bone grafting
Number of subjects: 98
Study 30706087 — intervention group
Group type: COMPARATOR
Intervention: Traditional uncemented primary THR technique
Number of subjects: 98
Study 28684845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple fresh fecal microbiota transplants (FMT)
Number of subjects: 25
Study 26283236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 5 mg twice daily
Number of subjects: 13
Study 26283236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23392450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 200
Study 23392450 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 200
Study 21762974 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 90
Study 21762974 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 600 mg
Number of subjects: 90
Study 21762974 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 75 mg
Number of subjects: 90
Study 21762974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19668245 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood-stabilizing drug or neuroleptic in severe cases
Number of subjects: 0
Study 19668245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium or anticonvulsant for prophylaxis
Number of subjects: 0
Study 19668245 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of brief outbursts of excessive emotion (especially anger)
Number of subjects: 0
Study 16965864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 56
Study 16965864 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 56
Study 15712502 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular training plus the Wingate 5-step mental training program (adapted for swimming)
Number of subjects: 40
Study 15712502 — intervention group
Group type: COMPARATOR
Intervention: Regular training plus relaxing activities
Number of subjects: 40
Study 12418596 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol delivered via HFA134a pMDI
Number of subjects: 10
Study 12418596 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol delivered via Turbuhaler
Number of subjects: 10
Study 12418596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9507989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low DHA (0.75 g/day)
Number of subjects: 100
Study 9507989 — intervention group
Group type: EXPERIMENTAL
Intervention: High DHA (1.50 g/day)
Number of subjects: 100
Study 9507989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (DHA-free)
Number of subjects: 100
Study 7883122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexokinase II gene analysis using PCR and SSCP screening
Number of subjects: 59
Study 1982761 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (100, 200, 400 micrograms)
Number of subjects: 9
Study 1982761 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100, 200, 400 micrograms)
Number of subjects: 9
Study 1982761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 360366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod treatment
Number of subjects: 42
Study 360366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 42
Study 30257549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, increased to 150 mg if LDL-C ≥ 70 mg/dL at week 8)
Number of subjects: 83
Study 30257549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 83
Study 30257549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 28352063 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin infusion
Number of subjects: 43
Study 28352063 — intervention group
Group type: COMPARATOR
Intervention: Gastric lavage
Number of subjects: 43
Study 28352063 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin + gastric lavage
Number of subjects: 43
Study 28352063 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 43
Study 28352063 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study 25711435 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy post-fibrinolysis
Number of subjects: 1059
Study 25711435 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1059
Study 23343951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium extended removal followed by extended conjunctival transplant
Number of subjects: 395
Study 23343951 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no surgery)
Number of subjects: 395
Study 21184067 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidermal and dermal replacement
Number of subjects: 30
Study 21184067 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin transplantation supplemented with Matriderm
Number of subjects: 30
Study 21184067 — intervention group
Group type: COMPARATOR
Intervention: Conventional full-thickness skin transplantation
Number of subjects: 30
Study 21184067 — intervention group
Group type: COMPARATOR
Intervention: Retroauricular perichondrodermal composite grafts
Number of subjects: 30
Study 19996038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 204
Study 19996038 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 204
Study 19996038 — intervention group
Group type: COMPARATOR
Intervention: Talking Control (TC)
Number of subjects: 204
Study 17726361 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional training program including moderate resistance exercise and balance exercise twice weekly for 6 months
Number of subjects: 65
Study 17726361 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=33)
Number of subjects: 65
Study 15479135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxemic congenital heart diseases
Number of subjects: 0
Study 15479135 — intervention group
Group type: COMPARATOR
Intervention: Normoxemic congenital heart diseases
Number of subjects: 0
Study 11808868 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiocolchicoside, 4 mg ampoules (test formulation)
Number of subjects: 12
Study 11808868 — intervention group
Group type: COMPARATOR
Intervention: Muscoril, 4 mg ampoules (reference formulation)
Number of subjects: 12
Study 10101929 — intervention group
Group type: EXPERIMENTAL
Intervention: Well metabolically controlled diabetic patients (group A)
Number of subjects: 50
Study 10101929 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly metabolically controlled diabetic patients (group B)
Number of subjects: 50
Study 10101929 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 50
Study 8089241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash products (5 different types)
Number of subjects: 14
Study 8089241 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine rinse product (positive control)
Number of subjects: 14
Study 8089241 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 14
Study 8089241 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC rinses (2 types)
Number of subjects: 14
Study 8089241 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer, essential oil/phenolic products
Number of subjects: 14
Study 30321767 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM) for 6 weeks (3 days a week, 10 times a day)
Number of subjects: 79
Study 30321767 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM)
Number of subjects: 79
Study 30321767 — intervention group
Group type: COMPARATOR
Intervention: No ESM (control group)
Number of subjects: 79
Study 28573716 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (category labels A and B)
Number of subjects: 0
Study 28573716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no category labels, stimuli labelled S1-S6)
Number of subjects: 0
Study 26406234 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Number of subjects: 31
Study 26406234 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training
Number of subjects: 31
Study 26406234 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 31
Study 23349486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 10 days
Number of subjects: 26
Study 23349486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 21 days
Number of subjects: 26
Study 23349486 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 21306296 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 0
Study 21306296 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI training)
Number of subjects: 0
Study 19928571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid and emoxypine during the first 10 days of standard chemotherapy
Number of subjects: 0
Study 19928571 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxypine
Number of subjects: 0
Study 19928571 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study 16987112 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) withdrawal for 3 months
Number of subjects: 157
Study 16987112 — intervention group
Group type: EXPERIMENTAL
Intervention: HDQoL questionnaire
Number of subjects: 157
Study 12820283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal microbicide
Number of subjects: 0
Study 12820283 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-truncated models
Number of subjects: 0
Study 12820283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture models
Number of subjects: 0
Study 10860211 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blind placebo 'run-in' or 'washout' periods
Number of subjects: 0
Study 10860211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10166596 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback plus reminders
Number of subjects: 2409